Ferreira Patricia, Roela Rosimeire Aparecida, Lopez Rossana Veronica Mendoza, Del Pilar Estevez-Diz Maria
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil.
Oncotarget. 2020 Mar 24;11(12):1085-1095. doi: 10.18632/oncotarget.27246.
To accomplish a systematic review of literature with overall survival meta-analysis about the role of microRNA in epithelial ovarian cancer as prognostic and predictive factor to chemotherapy response. A search was conducted in the PubMed database, using the keywords "microRNA" and "ovarian cancer" or "miRNA" and "ovarian cancer". Original articles published before 02/02/2019 that had as main subject microRNA (miRNA) and ovarian cancer were included. We considered for inclusion only studies that associated microRNA to chemotherapy-related diagnosis, prognosis, or response in ovarian cancer. The literature search returned 1,482 articles, 497 of which fulfilled inclusion criteria, yielding 350 miRNAs. The status of each miRNA was assessed in serum and tissue of ovarian cancer, benign tumors, and healthy tissue. The status of up-/downregulation of miRNAs was related to prognostic features (overall survival and disease-free survival) and response predictive features such as platinum and paclitaxel sensitivity/resistance. The miRNAs that had been cited three or more times were selected for prognostic and response predictive features analysis. Twelve miRNAs fulfilled all these criteria and were included in the overall survival meta-analysis. miRNAs affect virtually all mechanisms of carcinogenesis, working as either oncogenes or tumor suppressor genes. In this systematic review we identified miRNAs that may be related to prognosis, diagnosis, and chemotherapy sensitivity. The 12 miRNAs identified here should be included in future studies for validation.
为了对关于微小RNA在上皮性卵巢癌中作为预后和化疗反应预测因子的作用进行系统的文献综述及总生存meta分析。在PubMed数据库中进行了检索，使用关键词“微小RNA”和“卵巢癌”或“miRNA”和“卵巢癌”。纳入2019年2月2日前发表的以微小RNA（miRNA）和卵巢癌为主要主题的原创文章。我们仅纳入将微小RNA与卵巢癌化疗相关诊断、预后或反应相关联的研究。文献检索返回1482篇文章，其中497篇符合纳入标准，产生350种miRNA。在卵巢癌、良性肿瘤和健康组织的血清和组织中评估每种miRNA的状态。miRNA上调/下调状态与预后特征（总生存和无病生存）以及反应预测特征如铂和紫杉醇敏感性/耐药性相关。选择被引用三次或更多次的miRNA进行预后和反应预测特征分析。12种miRNA符合所有这些标准并被纳入总生存meta分析。miRNA几乎影响癌症发生的所有机制，充当癌基因或抑癌基因。在本系统综述中，我们鉴定出可能与预后、诊断和化疗敏感性相关的miRNA。此处鉴定出的12种miRNA应纳入未来研究进行验证。
